VanEck Biotech ETF (NASDAQ:BBH) Short Interest Up 28.6% in August

VanEck Biotech ETF (NASDAQ:BBH) was the target of a significant increase in short interest in the month of August. As of August 15th, there was short interest totaling 4,500 shares, anincreaseof28.6% from the July 31st total of 3,500 shares. Based on an average daily volume of 8,200 shares, the days-to-cover ratio is currently 0.5 days. Based on an average daily volume of 8,200 shares, the days-to-cover ratio is currently 0.5 days.

VanEck Biotech ETF Price Performance

Shares of BBH stock traded down $0.35 during mid-day trading on Tuesday, hitting $167.57. The company had a trading volume of 321 shares, compared to its average volume of 9,988. VanEck Biotech ETF has a 52-week low of $135.34 and a 52-week high of $183.21. The stock’s 50 day moving average price is $162.13 and its 200-day moving average price is $155.93.

Institutional Investors Weigh In On VanEck Biotech ETF

A number of hedge funds have recently bought and sold shares of the business. Osaic Holdings Inc. increased its position in VanEck Biotech ETF by 87.1% during the second quarter. Osaic Holdings Inc. now owns 1,465 shares of the company’s stock valued at $225,000 after acquiring an additional 682 shares during the last quarter. Corient Private Wealth LLC increased its position in VanEck Biotech ETF by 63.5% during the second quarter. Corient Private Wealth LLC now owns 13,290 shares of the company’s stock valued at $2,037,000 after acquiring an additional 5,160 shares during the last quarter. Bank of America Corp DE increased its position in VanEck Biotech ETF by 17.7% during the second quarter. Bank of America Corp DE now owns 52,466 shares of the company’s stock valued at $8,042,000 after acquiring an additional 7,898 shares during the last quarter. Raymond James Financial Inc. increased its position in VanEck Biotech ETF by 245.9% during the second quarter. Raymond James Financial Inc. now owns 67,940 shares of the company’s stock valued at $10,414,000 after acquiring an additional 48,297 shares during the last quarter. Finally, Rockefeller Capital Management L.P. increased its position in VanEck Biotech ETF by 2.6% during the second quarter. Rockefeller Capital Management L.P. now owns 11,811 shares of the company’s stock valued at $1,811,000 after acquiring an additional 294 shares during the last quarter. Hedge funds and other institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.